Novel Immunotherapies for Osteosarcoma
Reads0
Chats0
TLDR
The OS tumor microenvironment is reviewed and the promising immunotherapies available in the management of OS are appraised to help overcome the drawbacks of conventional treatments.Abstract:
Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting adolescents and young adults, which often progresses to pulmonary metastasis and leads to the death of OS patients. OS is characterized as a highly heterogeneous cancer type and the underlying pathologic mechanisms triggering tumor progress and metastasis are incompletely recognized. Surgery combined with neoadjuvant and postoperative chemotherapy has elevated 5-year survival to over 70% for patients with localized OS tumors, as opposed to only 20% of patients with recurrence and/or metastasis. Therefore, novel therapeutic strategies are needed to overcome the drawbacks of conventional treatments. Immunotherapy is gaining momentum for the treatment of OS with an increasing number of FDA-approved therapies for malignancies resistant to conventional therapies. Here, we review the OS tumor microenvironment and appraise the promising immunotherapies available in the management of OS.read more
Citations
More filters
Journal ArticleDOI
Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters
TL;DR: The maneuvers that cancer stem cells devise for eluding cell killing by the classic cytotoxic therapies used in osteosarcoma are revisited, highlighting studies that demonstrate the complex crosstalk of signaling pathways thatcancer stem cells can recruit to become chemoresistant.
Journal ArticleDOI
Construction of a cuproptosis‐related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients
TL;DR: A novel cuproptosis-related lncRNA signature with high reliability and accuracy for predicting outcome and immunotherapy response in osteosarcoma patients is developed, which provides new insights into the personalized treatment of osteosARcoma.
Journal ArticleDOI
Current State of Cold Atmospheric Plasma and Cancer‐Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels
TL;DR: In this article , a comprehensive and critical summary on the current understanding of mechanisms in which cold atmospheric plasma can assist anti-tumor immunity: induction of immunogenic cell death, oxidative post-translational modifications of the tumor and its microenvironment, epigenetic regulation of aberrant gene expression, and enhancement of immune cell functions.
Journal ArticleDOI
Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients
Long Hua,Pengfei Lei,Yihe Hu +2 more
TL;DR: In this paper , a predictive model of necroptosis-related genes (NRGs) in osteosarcoma for evaluating the tumor microenvironment and new targets for immunotherapy was established.
Journal ArticleDOI
Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy
TL;DR: In this review, the targets and radiotracers being investigated for monitoring the functional status of immune effector cells are summarized, and their use for imaging of immune-related responses are reviewed along their limitations and pitfalls.
References
More filters
Journal ArticleDOI
Cancer-related inflammation.
TL;DR: The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Journal ArticleDOI
Exploring the full spectrum of macrophage activation.
TL;DR: This Review suggests a new grouping of macrophages based on three different homeostatic activities — host defence, wound healing and immune regulation, and proposes that similarly to primary colours, these three basic macrophage populations can blend into various other 'shades' of activation.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Journal ArticleDOI
Macrophage plasticity and polarization: in vivo veritas
Antonio Sica,Alberto Mantovani +1 more
TL;DR: The identification of mechanisms and molecules associated with macrophage plasticity and polarized activation provides a basis for Macrophage-centered diagnostic and therapeutic strategies.
Journal ArticleDOI
Oncology Meets Immunology: The Cancer-Immunity Cycle
TL;DR: Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer and may be more effective in combination with agents that target other steps of the cycle.
Related Papers (5)
Circ0038632 modulates MiR-186/DNMT3A axis to promote proliferation and metastasis in osteosarcoma
Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis
Amal El-Naggar,Chansey J. Veinotte,Hongwei Cheng,Thomas G. P. Grunewald,Gian Luca Negri,Syam Prakash Somasekharan,Dale Corkery,Franck Tirode,Joan Mathers,Debjit Khan,Alastair H. Kyle,Jennifer H.E. Baker,Nancy E. LePard,Steven McKinney,Shamil Hajee,Momir Bosiljcic,Gabriel Leprivier,Cristina E. Tognon,Andrew I. Minchinton,Kevin L. Bennewith,Olivier Delattre,Yuzhuo Wang,Graham Dellaire,Jason N. Berman,Jason N. Berman,Poul H. Sorensen +25 more